A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.Fatima Karzai, William L. Dahut, Ravi A. Madan et al.|Journal of Clinical Oncology|2018Cited by 50
PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide.Shruti U. Gandhy, Ravi A. Madan, Seth M. Steinberg et al.|Journal of Clinical Oncology|2020Cited by 7
Immunotherapy for biochemically recurrent prostate cancer.Ravi A. Madan, James L. Gulley, Fatima Karzai et al.|Journal of Clinical Oncology|2018Cited by 6
Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.Mohammad Atiq, Ravi A. Madan, Fatima Karzai et al.|Journal of Clinical Oncology|2022Cited by 4
Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.Mohammad Atiq, Ravi A. Madan, Elias Bin Aris Chandran et al.|Journal of Clinical Oncology|2022Cited by 3